CD44 and breast carcinoma: Immunohistochemistry and Western blotting results also showed that the CD44 expression was significantly higher in T allele carriers than in C allele carriers.22 Similar results were confirmed in a breast cancer study in which Jiang et al10 showed that breast cancer patients with CT and TT had higher levels of CD44 than CC genotype carriers, while the 5‐year survival rate of CT + TT patients was significantly lower.